Your AI-Trained Oncology Knowledge Connection!
Luspatercept-aamt achieved a 77.1% mean hemoglobin increase of 1.0 g/dL or higher from baseline over a continuous 12-week interval during weeks 13 to 24 in the absence of red blood cell transfusions vs 0% with placebo in patients with non-transfusion–dependent β-thalassemia.
The combination of lenalidomide and rituximab continued to improve progression-free survival with durable outcomes and a manageable safety profile in patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.
Although cardiovascular health of patients with myeloproliferative neoplasms was relatively good, an estimated 11% to 22% of patients were not prescribed appropriate medications for management of comorbidities associated with thrombotic risk.
Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma.
The fixed-dose combination of the BCL-2 inhibitor venetoclax and the humanized anti-CD20 monoclonal antibody obinutuzumab continued to confer a progression-free survival advantage over chlorambucil plus obinutuzumab for patients with previously untreated chronic lymphocytic leukemia.
Othman Al-Sawaf, MD, discusses the efficacy of venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia, as demonstrated in the phase 3 CLL14 trial.
Ruben A. Mesa, MD, discusses results seen with momelotinib in patients with transfusion-independent myelofibrosis, as demonstrated in the phase 3 SIMPLIFY-1 and SIMPLIFY-2 trials.
Intensified induction therapy with daratumumab in addition to cyclophosphamide, bortezomib, lenalidomide, and dexamethasone and bortezomib-augmented autologous stem cell transplant yielded robust responses in patients with ultra¬ high–risk multiple myeloma or primary plasma cell leukemia
Patients with relapsed/refractory multiple myeloma who were treated with ciltacabtagene autoleucel experienced improved outcomes over those who received a conventional therapy
Ciltacabtagene autoleucel demonstrated efficacious responses and significant improvements in survival over standard of care in triple class–relapsed/refractory multiple myeloma.
Zanubrutinib induced superior response and progression-free survival rates, as well as lower rates of atrial fibrillation/flutter than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
A 60 mg dose of zandelisib administered on an intermittent schedule from cycle 1 plus 80 mg of zanubrutinib twice daily yielded promising response rates in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.
The Japan Ministry of Health, Labour, and Welfare has granted conditional and time-limited approval to teserpaturev for the treatment of patients with malignant glioma; this is the first oncolytic virus to receive approval for use in this indication or any primary brain cancer.
Bijal Shah, MD, MS, discusses the key findings of the ZUMA-3 trial, as well as key safety information regarding brexucabtagene autoleucel as a treatment for patients with heavily pretreated patients with relapsed/refractory B-cell ALL.
Treatment with the allogeneic CAR T-cell product ALLO-501A elicited encouraging signals of clinical activity when used with ALLO-647 lymphodepletion in patients with relapsed/refractory large B-cell lymphoma who did not previously receive autologous CAR T-cell therapy.
The incidence of grade ≥2 cytokine release syndrome was lower in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a B-cell maturation antigen-targeted CAR T-cell therapy.
A revolutionary new urine screening test that utilizes a novel Keratin 17 cancer biomarker can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.
Week 24 transfusion independence was associated with an improvement in overall survival vs week 24 transfusion dependence in patients with myelofibrosis who were randomized to momelotinib in the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials.
Allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosis, according to findings from a systematic review and meta-analysis.
Lisocabtagene maraleucel demonstrated a highly significant improvement in event-free survival, complete response rate, and progression-free survival over standard of care in the second-line treatment of patients with relapsed/refractory large B-cell lymphoma, meeting primary and secondary end points of the phase 3 TRANSFORM trial.
The FDA approved the radiopharmaceutical agent technetium Tc 99m tilmanocept injection (Lymphoseek) for accurate and precise lymph node identification in pediatric patients with melanoma, rhabdomyosarcoma, and other types of solid tumors.
Although circulating tumor cell analysis of patients with HER2-negative metastatic breast cancer identified patients with CTC amplification, the utility of subsequent HER2-directed treatment with trastuzumab plus vinorelbine in this patient population was low.
Practices participating in the Oncology Care Model, an experimental payment model developed by the Center for Medicare and Medicaid Innovation, are incentivized to improve patient experiences and outcomes by providing enhanced services and care while bending the total cost curve.
In an effort to build on the efficacy demonstrated with ruxolitinib, investigators are evaluating combination therapies—specifically the dual inhibition of the JAK-STAT and BET pathways using pelabresib, a novel BET inhibitor.
The combination of regorafenib plus pembrolizumab in the first-line setting for patients with advanced hepatocellular carcinoma showed encouraging anti-tumor activity with a disease control rate of 91%, and did not display any new safety signals.
The hypoxia-inducible factor-2 alpha inhibitor belzutifan maintained clinical efficacy with further follow-up in patients with Von-Hippel Lindau–associated renal cell carcinoma, as well as other VHL-associated neoplasms.
Cabozantinib exposure was not significantly associated with progression-free survival but appeared to predict high rates of palmar-plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma treated with the frontline combination of cabozantinib and nivolumab.
The addition of lenvatinib to pembrolizumab elicited a notable survival benefit and improved responses over single-agent sunitinib in patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups.
The European Medicines Agency has granted marketing authorization to duvelisib for single-agent use in patients with relapsed/refractory chronic lymphocytic leukemia who have previously received at least 2 therapies or those with follicular lymphoma whose disease is refractory to at least 2 previous systemic therapies.
